Filters
Corrected T1 (cT1) is the most appropriate diagnosis and monitoring tool for widespread adoption of resmetirom treatment in the United States
Hancock, M., et al (2025)
Journal of Medical Economics
Read Summary ▾
cT1-based pathway to assign suspected MASH patients to resmetirom and monitor response delivered the lowest per-patient costs in the VA: $7,022 (cT1) vs $7,268 (biopsy) vs $28,509 (VCTE), in the base-case and scenario analyses. Choose cT1: more efficient treatment allocation, better care, lower spend
Real-world assessment of liver corrected T1 and magnetic resonance elastography in predicting liver disease progression.
Corey K. E., et al (2025)
Liver International
Read Summary ▾
Guidelines prioritise early detection of chronic liver disease progression risk. To avoid biopsy, NITs have become part of standard‐of‐care. Across etiologies, patients with low fibrosis risk by MRE but high disease activity by cT1 have ~threefold higher progression, showing cT1 flags risk earlier than stiffness alone. Integrating cT1 into care pathways improves stratification and proactive management without biopsy.
Exploring the role of MRCP+ for enhancing detection of high-grade strictures in primary sclerosing cholangitis
Franklin, J., et al. (2025)
Journal of Clinical Medicine
Read Summary ▾
Adding quantitative MRCP+ metrics to standard MRCP improves radiologists’ confidence and agreement in detecting high-grade strictures in primary sclerosing cholangitis patients. MRCP+ reduces variability, enhances diagnostic reliability, and may help standardize assessments, potentially improving patient management and treatment decisions
Automatic Couinaud segmentation using AI and pictorial representation based landmarking
Nunez, L., et al. (2025)
Abdominal Radiology
Read Summary ▾
This study presents a deep learning framework for accurate, personalized Couinaud liver segment localization using MRI data. It outperforms existing methods in landmark placement and segment volume estimation, is explainable, adaptable across imaging types, and scalable, potentially improving liver surgery planning and clinical workflow efficiency
Left atrial volume quantification by transthoracic echocardiography versus cardiovascular magnetic resonance imaging: a systematic review and meta-analysis
Mahmod, M., et al. (2025)
The International Journal of Cardiovascular Imaging.
Read Summary ▾
Left atrial volume (LAV) is key in diagnosing heart failure with preserved ejection fraction. Compared to cardiovascular magnetic resonance (CMR), transthoracic echocardiography frequently fails or underestimates LAV, misclassifying enlargement in 38% of cases. CMR remains the more accurate gold standard for LAV assessment
Practical applications of AI in body imaging
Mervak, B. M., et al (2025)
Abdominal Radiology
Read Summary ▾
AI and deep learning are reshaping radiology, offering improved accuracy, efficiency, and automation. This review highlights FDA-cleared AI tools for abdominopelvic imaging available in the U.S. by late 2024, explores their clinical value, and outlines opportunities for future innovation
High prevalence of MASLD in psoriasis and psoriatic arthritis assessed with multiparametric magnetic resonance imaging
James, L., et al. (2025)
Rheumatology
Read Summary ▾
Psoriatic disease (PsD) patients show a high prevalence of metabolic liver conditions (44% with MASLD and 22% with MASH) despite normal blood tests. Rates exceed those in matched controls and occur regardless of methotrexate use, highlighting the need for routine liver screening in PsD management e.g. by multiparametric MRI
TERN-501 monotherapy and combination therapy with TERN-101 in metabolic dysfunction-associated steatohepatitis: the randomized phase 2a DUET trial
Noureddin, M., et al. (2025)
Nature Medicine
Read Summary ▾
TERN-501, a THRβ agonist, significantly reduced liver fat in a dose-dependent manner over 12 weeks in patients with MASH. Compared to placebo, MRI-PDFF and cT1 reductions were substantial, and significantly more participants receiving TERN-501 achieved a clinically significant change in cT1 by 6 weeks.
Multiparametric magnetic resonance imaging may improve detection of patients with at-risk MASH: Real world experience in hepatology clinics
Phipps, M. M., et al. (2025)
Digestive and Liver Disease
Read Summary ▾
Multiparametric MRI detected increased risk of MASH or advanced fibrosis in over half of MASLD patients classified as low risk by FIB-4. Early use of multiparametric MRI could identify at-risk patients, particularly women and those with diabetes, enabling timely intervention and better disease management compared to current guideline-based risk stratification.
Cardiac and liver impairment on multi-organ MRI and risk of major adverse cardiovascular and liver events
Jackson E., et al. (2025)
Nature Medicine
Read Summary ▾
Among UK Biobank participants with MRI, elevated liver cT1 and reduced left-ventricular ejection fraction independently—or in combination—predicted cardiovascular and liver events and all-cause mortality. Cardiac and hepatic impairment often coexisted, supporting multi-organ MRI as a tool for integrated risk stratification and prevention pathways spanning heart and liver disease.
Quantitative MRCP metrics as imaging biomarkers to differentiate benign from malignant bile duct obstructions
Eurboonyanun, K., et al. (2025)
Frontiers in Oncology
Read Summary ▾
Quantitative MRCP metrics, especially total biliary tree volume, effectively distinguished malignant from benign biliary obstructions. A volume ≥25 ml predicted malignancy with good accuracy (AUC 0.79). These findings support MRCP+ as a non-invasive, contrast-free tool for identifying cholangiocarcinoma, potentially aiding earlier diagnosis and improving patient outcomes.
Phase 3 trial of semaglutide in metabolic dysfunction–associated steatohepatitis
Sanyal, A. J., et al. (2025)
New England Journal of Medicine
Read Summary ▾
Once-weekly semaglutide significantly improved liver histology in patients with MASH and fibrosis, compared to placebo. It also achieved substantial weight loss, although gastrointestinal side effects were more common. Semaglutide improved noninvasive liver markers, though the high placebo response underscores the need for more precise monitoring tools.
Severe Dietary Energy Restriction for Compensated Cirrhosis Due to Metabolic Dysfunction‐Associated Steatotic Liver Disease: A Randomised Controlled Trial
Koutoukidis, D. A., et al. (2025)
Journal of Cachexia, Sarcopenia and Muscle
Read Summary ▾
Severe energy restriction safely induced significant weight loss and reduced liver fat in patients with compensated cirrhosis due to MASLD (CC-MASLD). No adverse effects or liver deterioration were observed, while both MRI-PDFF and cT1 were significantly reduced. These promising results support further research into diet-based interventions for CC-MASLD management
Accuracy, repeatability, reproducibility and reference ranges of primary sclerosing cholangitis specific biomarkers from quantitative MRCP
Harisinghani, M., et al. (2025)
Abdominal Radiology
Read Summary ▾
Quantitative MRCP-derived metrics showed high accuracy, repeatability, and reproducibility across scanners, effectively distinguishing healthy individuals from PSC patients. These findings support the use of MRCP+ metrics for assessing biliary health and their suitability for multi-centre clinical trials and longitudinal monitoring in liver disease